Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (US20170262608) METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS

Office : United States of America
Application Number: 15606824 Application Date: 26.05.2017
Publication Number: 20170262608 Publication Date: 14.09.2017
Publication Kind : A1
IPC:
G06F 19/00
G06F 19/28
G PHYSICS
06
COMPUTING; CALCULATING; COUNTING
F
ELECTRIC DIGITAL DATA PROCESSING
19
Digital computing or data processing equipment or methods, specially adapted for specific applications
G PHYSICS
06
COMPUTING; CALCULATING; COUNTING
F
ELECTRIC DIGITAL DATA PROCESSING
19
Digital computing or data processing equipment or methods, specially adapted for specific applications
10
Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
28
for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures
CPC:
G06F 19/3418
G06F 19/28
G06F 19/30
Applicants: uBiome, Inc.
Inventors: Zachary Apte
Jessica Richman
Daniel Almonacid
Priority Data:
Title: (EN) METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS
Abstract: front page image
(EN)

A method for diagnosing and treating an immune microbial dysfunction in a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the immune microbial dysfunction based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset, wherein the characterization is diagnostic of at least one of Crohn's disease, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), ulcerative colitis, and celiac disease; based upon the characterization, generating a therapy model configured to correct the immune microbial dysfunction; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.